Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Abstract: This paper proposes a new recursive implementation of the Gaussian filter. Previous recursive implementations of the Gaussian filter suffer from one or several drawbacks. Some methods ...

Abstract: This paper studies the control-oriented recursive identification of finite impulse response systems with binary-valued observations. Inspired by the Maximum Likelihood method, a novel ...

To use this trace, just keep clicking on the ``Make one step'' button. You can use the ``Finish this call'' button to skip to the step after finishing the current level. The call stack in the display ...

Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving -5.12% from the previous trading session. This change lagged the S&P 500's daily loss of 1.62%. Meanwhile, the Dow ...

Ben Taylor, CFO of Recursion, here with us. Thanks so much for joining us. Sure. Great. And first of all, thanks for having us here, Tommie. This is always a terrific conference and great to be here.

Buy: Anthropic exposure via its likely IPO/secondary path (e.g., IPO allocation or liquid proxy like AI-safety/compute beneficiaries). Rationale: Anthropic is pushing “slow/pause” policy while still ...